II PhD Conference
"Transparency and Accountability in Scientific Research"
Kyiv-Mohyla Academy Doctoral School
January 31, 2013 – February 4, 2013

Maternal characteristics and risk factors of Hepatitis C co-infection in HIV positive pregnant women in Ukraine

Slobodianyk Liudmyla
DP Public health administration
Academic supervisor: Andreeva Tatiana

Background


 HIV and Hepatitis C are major burdens on the health care system in Ukraine

Estimated prevalence (2011):


HIV - 0.58% (230,000 people)

HCV - 3% (1,350,000 people)

Officially registered new HIV cases, by years (1987 – 2011)




Registered HIV Prevalence for Adults and Children Living with HIV, by region of Ukraine, end-2007 *



^{*} among citizens of Ukraine diagnosed with HIV and under medical observation

Changing the way of HIV transmission, 2000-2011



HCV in HIV epidemic setting

Official statistics:

before 2003 – no data

since 2003 - acute cases have been registered

since 2009 – registration of chronic cases has started

Prevalence HCV/HIV co-infection among risk groups:

70-95% of people living with HIV are co-infected with HCV (1) IDU – 80-90% (2,3,4)

Differences in transmission efficiencies of HIV and HCV

HCV as biological marker of injecting behavior

- 1 Aceijas, C. and Rhodes, T. (2007) Global Estimates of Prevalence of HCV Infection among Injecting Drug Users. International Journal of Drug Policy 18: 352–358.
- 2 HIV/AIDS TREATMENT AND CARE CLINICAL PROTOCOLS FOR THE WHO EUROPEAN REGION, Ch.6, 2007
- 3 Thomas DL, Leoutsakas D, Zabransky T, Kumar MS. Hepatitis C in HIV-infected individuals: cure and control, right now. *Journal of the International AIDS Society.* 2011;14:22.
- 4 Strader DB. Co-infection with HIV and Hepatitis C Virus in Injection Drug Users and Minority Populations. Clin Infect Dis. 2005;41(Supplement 1):S7-S13.

Hypothesis

HCV co-infection in HIV positive women is associated with IDU women or their partners

Research questions


What the proportion of traditional risk groups (IDUs, sex workers, prisoners) among of women and their sexual partners?

What is the prevalence of HCV/HIV co-infection among study population?

Which risk factors are associated with HCV coinfection in HIV-positive women?

Methodology

- Secondary data analysis
- Cross-sectional design
- Study population:
 - HIV positive women who were pregnant in 2009-2010, gave birth to child/children in 2010-2011 and sought antenatal care at medical facilities (pregnancy monitoring and/or delivery)
- Sampling 22 regional AIDS centers (out of 27) participated
- 879 participants
- In-person interview (April-July 2011) + data from medical records (HIV related information, HCV tests results)



Statistical analysis

- Univariate analysis
- Chi-squared test of independence (p-value $<0.15 \alpha$ -level)
- Poisson regression with robust variance estimates at 95% CI

Findings: maternal behavioral characteristics

r illulings. Illaterilai bellaviorai cilaracteristics				
Characteristics	n=618	(%)		
Injection drug using				
Yes	61	(9.9)		
No	557	(90.1)		
Alcohol drinking				
Yes	512	(82.8)		
No	106	(17.2)		
Smoking				
Yes	224	(36.2)		
No	394	(63.8)		
History of sexual abuse	11	(1.8)		
History of imprisoning	6	(1.0)		
History of commercial sex	5	(0.8)		
History of blood transfusion	6	(1.0)		
History of a lot of medical manipulation	22	(3.6)		
	37	(6.0)		

Findings: maternal behavioral characteristics

132 (21.4)

103 (16.7)

182 (22.4)

39 (6.3)

12 (1.9)

51 (8.2)

13

Characteristics	n=618	(%)
HIV status of permanent partner		
Positive	206	(33.3)
Negative	79	(12.8)
Unknown	333	(53.9)
Reported risks of permanent		
partners		

IDU

Has STD


Alcohol abuse

Contact with HIV+


Former prisoner

Numerous sexual contacts


HCV prevalence among HIV positive women




HCV prevalence among HIV positive women, by IDU status




HCV prevalence among HIV positive women, by HIV prevalence in region of residence




HCV prevalence among HIV positive women, by IDU status



HCV prevalence among HIV positive women, by IDU status of permanent partner





Association between risk factors and HCV co-infection among 557 non-injection drug using women with HIV

Riveriate Multivariate

yes

no

yes

no

yes

no

Marital status

law)

Age

Imprisoning permanent partner

19 and younger

Sexually transmitted infections

Married (official/common

20 and older

injection drug using women with HIV						
Factors	N=557	HCV positiv e	%	χ² p-value	Bivariate analyses, (95%CI)	Multivariate analysis, (95%CI)
Regions				p=0.002		
HIV prev. > 300/100,000	203	40	19.7		2.0 (1.3 - 3.0)	1.9 (1.3 – 2.8)
Other regions	354	35	10.0		1.00	1.00
IDU permanent partner				p=0.002		

22

53

10

65

68

24

51

68

24.5

11.4

21.7

12.7

30.4

12.7

19.1

11.8

14.2

p=0.086

p=0.015

p=0.037

p=0.210

90

467

46

511

23

534

126

431

479

2.2(1.4-3.4)

1.00

1.7(0.9 - 3.1)

1.00

2.4 (1.2 - 4.6)

1.00

1.6(1.0-2.5)

1.00

1.00

1.9(1.3 - 2.9)

1.00

1.7(0.9 - 3.0)

1.00

2.1(1.2-3.7)

1.00

1.7(1.1 - 2.6)

1.00

1.00

20

Main findings

- The HCV infection among HIV positive women in Ukraine is linked to the IDU practice both women and her partners
- Strong association between high HIV prevalence in the region of women's residence and HIV/HCV co-infection support the unsafe injection behavior as the most important route of HCV transmission
- These is urgent need to increase the HCV testing of pregnant women, particularly who are IDU and women who has IDU partners

STRENGTH AND LIMITATIONS


STRENGTHS:

- participants from 22 regional AIDS centers (out of 27) representative for Ukraine
- Laboratory confirmed tests results

LIMITATIONS:


- cross-sectional design
- Self-reported information
- considering past HCV infection as current
- Donetsk region out of sample HIV/HCV prevalence may be underreported
- Obtained information may be not representative for women with fertility problem and who are 36 and older

Modes of HIV transmission, 2010



- drug injection
- heterosexual way
- mother-to-child transmission
- undefined

Number of new AIDS cases and AIDS-related death, Ukraine 1991 – 2011



Methodology

This project is a part of in-depth study of determining the current stage of HIV infection in Ukraine and their potential for generalization of the epidemic process (Global Fund to Fight AIDS, Tuberculosis and Malaria through the ICF "International HIV / AIDS Alliance in Ukraine ")

HIV AND AIDS ESTIMATES, Ukraine (2011)

Number of people living with HIV

230,000 [180,000 - 310,000]

Adults aged 15 to 49 prevalence rate

0.8% [0.6% - 1%]

Adults aged 15 and up living with HIV

230,000 [180,000 - 300,000]

Women aged 15 and up living with HIV

94,000 [71,000 - 120,000]

Deaths due to AIDS

22,000 [16,000 - 30,000]

Background

HIV prevalence among pregnant women in recent years is growing (1)

In 2007 - HIV prevalence in this group was 0.52% (at the first half of 2009 – 0,56%, in some regions – more than 1%) (2)

^{1 -} Comprehensive External Evaluation of the national response to AIDS in Ukraine: Summary Report (English original, January 2009)

^{2 -} HIV infection in Ukraine. Newsletter number 35/ market, publications. MOH. - Kyiv, 2010. - Access mode: http://stop-aids.gov.ua. - Title screen.

Factors influence HIV/HCV acquisition in women

SES, employment status, kind of occupation (medical staff, migrants, sexual harassment risks at work)

Grown et al., 2005:542; Buve et al., 2002:2014, 2016; Gilbert & Walker, 2002:1103; Kehler, 2001:1; Amaro & Raj, 2000:724; Preston-Whyte, 1995:220; Gianelli et al., 2010:542)

Gender balance of power (women's victmization in relationships)

Jones & Oliver, 2007:812; Campbell, Foulis, Maimane & Sibiya, 2005:813; Shearer et al., 2005:322; Tiessen, 2005:14; Andersson et al., 2004:952; Greig & Koopman, 2003:197; Kim & Motsei, 2002:1251; Umerah-Udezulu, 2001:4; UNAIDS, 2001:23-24; Vundule et al., 2001:73; Amaro & Raj, 2000:726; Wood & Jewkes, 1998:12-15, 24; Pettifor et al., 1996:1996

Education (less educated women are more likely to HIV because of lower economical status, dependence on partner)

Kongolo & Bamgose, 2002:86; Bowleg, Belgrave & Reisen, 2000:614

Age (in context of age of the first sexual debut, age difference between woman and her sexual partner)

Gilbert & Walker, 2002:1094; Gregson, Nyamukapa, Garnett, Mason, Zhuwau, Carael, Chandiwana & Anderson, 2002:1899; Department of Health South Africa, 2000:8; UNAIDS, 2000:11; Gray, Wawer, Brookmeyer, Sewankambo, Serwadda, Wabwire-Mangen, Lutalo, Li, Van Cott, Quinn & Rakai Project Team, 2001:1153; Pettifor et al., 1996:2003)

Marital status (monogamy as protective factor for HIV)

Bennetts (1999:649), Utulu (2007:401) Sia E Msuya (2006:3-2) Msisha (2008:1301).

Factors influence HIV/HCV acquisition in women

Sexual behavior (multiple sexual partners, extramarital sex by both partners, polygamy, unsafe sex (condom use + alcohol)

Sagay 2005:65; Johri (2010:793); Utulu 2007:40; Veldhuijzen 2011:254; Eaton et al., 2003:159; Karim et al., 2003:18; Morrison et al., 2003:162; LaBrie, Schiffman & Earlywine, 2002:145

Injection behavior (shared route of HIV and HCV transmission)

- unsafe drug injection
- non-medical injection (tatoo, piersing, ect.)

HCV in HIV epidemic setting (1)

HIV/HCV co-infection:

- affects disease progression related to both agents
- increase the rate of liver cirrhosis (people survive to develop HCV-related cirrhosis)
- challenges the clinical management and treatment of both infection
- increases hepatotoxicity of ARV therapy and treatment discontinuation

HCV in HIV epidemic setting

Official statistics:

before 2003 - no data

since 2003 - acute cases have been registered

since 2009 – registration of chronic cases has started

Prevalence HCV/HIV co-infection among risk groups:

70-95% of people living with HIV are co-infected with HCV (1)

MSM - 3-8%(2,3)

IDU - 80-90% (4)

Differences in transmission efficiencies of HIV and HCV

HCV as biological marker of injecting behavior

- 1 Aceijas, C. and Rhodes, T. (2007) Global Estimates of Prevalence of HCV Infection among Injecting Drug Users. International Journal of Drug Policy 18: 352–358.
- 2 HIV/AIDS TREATMENT AND CARE CLINICAL PROTOCOLS FOR THE WHO EUROPEAN REGION, Ch.6, 2007
- 3 Thomas DL, Leoutsakas D, Zabransky T, Kumar MS. Hepatitis C in HIV-infected individuals: cure and control, right now. *Journal of the International AIDS Society*. 2011;14:22.

Predictor variables

- 1) <u>socio demographic factors</u> (the place of residence, region of residence, age, marital status, education)
- 2) <u>behavioral risk factors</u> (alcohol drinking, smoking, injection drugs using, history of imprisoning, history of commercial sex
- 3) <u>medical risk factors</u> (history of blood transfusion, surgery, numerous medical manipulation, abortion, non-medical contacts tattoo, piercing)
- 4) <u>history of sexually transmitted infections</u> (syphilis, gonorrhea, chlamidiasis, herpes, trichomoniasis, candidiasis)
- 5) risk factors related to the permanent and casual partners

Outcome variable

HCV serostatus

Women were considered as HCV seropositive if any HCV test result (anti-HCV, HCV core antigen, PCR test for Hepatitis C virus RNA) was recorded as positive.

Outline

- Background
- Objective
- Methodology
- Findings
- Limitations
- Discussion

HCV in HIV epidemic setting

Prevalence HCV/HIV co-infection among risk groups:

70-95% of people living with HIV are co-infected with HCV (1)

MSM - 3-8%(2,3)

IDU - 80-90% (4)

Differences in transmission efficiencies of HIV and HCV

HCV as biological marker of injecting behavior

^{1 -} Aceijas, C. and Rhodes, T. (2007) Global Estimates of Prevalence of HCV Infection among Injecting Drug Users. International Journal of Drug Policy 18: 352–358.

^{2 -} HIV/AIDS TREATMENT AND CARE CLINICAL PROTOCOLS FOR THE WHO EUROPEAN REGION, Ch.6, 2007

^{3 -} Thomas DL, Leoutsakas D, Zabransky T, Kumar MS. Hepatitis C in HIV-infected individuals: cure and control, right now. *Journal of the International AIDS Society*. 2011;14:22.

^{4 -} Strader DB. Co-infection with HIV and Hepatitis C Virus in Injection Drug Users and Minority Populations. Clin Infect Dis. 2005;41(Supplement 1):S7-S135

HCV in HIV epidemic setting

Official statistics:

before 2003 - no data

since 2003 - acute cases have been registered

since 2009 – registration of chronic cases has started

Prevalence HCV/HIV co-infection among risk groups:

70-95% of people living with HIV are co-infected with HCV (1)

MSM - 3-8%(2,3)

IDU - 80-90% (4)

Differences in transmission efficiencies of HIV and HCV

HCV as biological marker of injecting behavior

- 1 Aceijas, C. and Rhodes, T. (2007) Global Estimates of Prevalence of HCV Infection among Injecting Drug Users. International Journal of Drug Policy 18: 352–358.
- 2 HIV/AIDS TREATMENT AND CARE CLINICAL PROTOCOLS FOR THE WHO EUROPEAN REGION, Ch.6, 2007
- 3 Thomas DL, Leoutsakas D, Zabransky T, Kumar MS. Hepatitis C in HIV-infected individuals: cure and control, right now. *Journal of the International AIDS Society.* 2011;14:22.
- 4 Strader DB. Co-infection with HIV and Hepatitis C Virus in Injection Drug Users and Minority Populations. Clin Infect Dis. 2005;41(Supplement 1):S7-S13.

HIV risk groups

HIV prevalence HIV risk groups (2011)

IDU - 21,5%

FSW - 9%

Rationale

 The prevalence of HIV infection among pregnant quite accurately reflects and trends and HIV prevalence among the general population (1)

 HIV positive pregnant women can be link to high risk groups

Findings: maternal demographic characteristics

i in an igot materinar a emegrapine en aracteriouse			
Characteristics	n=618	(%)	
Place of residence			
urban	435	(70.4)	
rural	183	(29.6)	
Age			
19 and younger	24	(3.9)	
20-29	410	(66.4)	
30 and older	184	(29.7)	
Education			
Secondary education (complete or incomplete)	258	(41.7)	

(39.3)

(18.8)

(0.2)

(85.6)

(14.4)

243

116

529

89

Professional technical (after 8/9 or 10/11 grades)

Higher education (complete or incomplete)

Married (legally or common-law marriage)

Divorced /widow/never been married

Illiterate person

Marital status

Findings: maternal demographic characteristics

Characteristics	n=618	(%)
Alcohol drinking		
Yes	512	(82.8)
No	106	(17.2)
	17 years	
The average age respondents start to drink	(min 10 max 25)	
Smoking		
Yes	224	(36.2)
No	394	(63.8)
Smoking during pregnancy (among those who smoke)		
Yes	125	(55.8)
No	99	(44.2)
Injection drug using		
Yes	61	(9.9)
No	557	(90.1)
Age of sexual debut		
16 years and younger	199	(32.2)
17-19	279	(45.2)
20 and older	140	(22.6)
	17.3 40	

